Viking Therapeutics Inc (VKTX) concluded trading on Wednesday at a closing price of $32.23, with 4.47 million shares of worth about $143.99 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 117.62% during that period and on Wednesday the price saw a gain of about 5.33%. Currently the company’s common shares owned by public are about 100.11M shares, out of which, 89.74M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 61 times over the past 12 months. They bought 1,349,835 shares in 37 of the transactions. In 24 selling transactions, insiders dumped 1,490,123 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 31.66% in past 5 days and over the past one month there was a price change of 51.60%. Year-to-date (YTD), VKTX shares are showing a performance of 73.19% which increased to 203.20% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.28 but also hit the highest price of $32.00 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 2.95 million. The stock is currently trading 31.72% above its 20-day simple moving average (SMA20), while that difference is up 53.42% for SMA50 and it goes to 91.19% higher than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 100.11M outstanding shares and institutions hold larger chunk of about 75.47% of that.
The stock has a current market capitalization of $3.24B and its 3Y-monthly beta is at 0.55. It has posted earnings per share of -$0.91 in the same period. It has Quick Ratio of 19.19 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 9.32% while standing at 8.00% over the month.
Analysts are in expectations that Viking Therapeutics Inc (VKTX) stock would likely to be making an EPS of $Vertex Pharmaceuticals Incorpor in the current quarter, while forecast for next quarter EPS is $417.88 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $Nkarta, Inc. which is $MarketAxess Holdings, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Veritex Holdings, Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -24.51% while it is estimated to decrease by -31.02% in next year. EPS is likely to grow at an annualized rate of 40.00% for next 5-years, compared to annual growth of -18.89% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH MKM on May 31, 2023 offering a Buy rating for the stock and assigned a target price of $32 to it.
